Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Daiichi Sankyo to Insist on Achieving Numerical Goals: New President Nakayama
June 7, 2010
- Incentives for Use of Generics Boost Business of JGA Member Companies
June 7, 2010
- Astellas Aims at Sales of ¥1,100 Bil. In FY2014
June 7, 2010
- Meiji Seika: Pharm. Business Driven by Generics
June 7, 2010
- Women Receives Cervarix at 31.4 of Age on Average in Japan: GSK
June 7, 2010
- Teijin Pharma to Increase No. of MRs to Market TMX-67
June 7, 2010
- Zeria Aims at Overseas Sales Ratio of >25%: President Ibe
June 7, 2010
- Major New Entrants in Generics Market, Emergence of AGs
June 7, 2010
- Takeda Aims at Top Share for DPP-4 Inhibitors with Nesina
June 7, 2010
- Asahi Kasei Pharma: Sales Down 8.2% to ¥56.0 Bil.
June 7, 2010
- Revlimid, Torisel Recommended for Approval
June 7, 2010
- Mark Smith Appointed President of Merck Serono in Japan
June 7, 2010
- Yakult: Campto Patent Expiration Hits Pharm. Business
June 7, 2010
- Industry Should Generate Visible Benefits of New Premium System: Dr Suzuki of JMA
June 7, 2010
- Ethical Drugs' Sales Up 4.7% in FY2009: Crecon
June 7, 2010
- Fuso: Pharm. Sales Up 1.5% Driven by Dialysis-Related Products
June 7, 2010
- AZ, J&J to Jointly Develop CAPS System in Japan
June 7, 2010
- Average Operating Profit Rate Up to 0.57% for Top-4 Wholesalers
June 7, 2010
- ASKA: Large Drop in Profits Despite 17.6% Increase in Sales
June 7, 2010
- Takara Bio: Sales Up 2.2% to ¥19,325 Mil.
June 7, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…